173 related articles for article (PubMed ID: 22095049)
21. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
22. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
23. New developments in the therapy of pulmonary fibrosis.
Scriabine A; Rabin DU
Adv Pharmacol; 2009; 57():419-64. PubMed ID: 20230768
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Nathan SD; Wuyts WA; Mogulkoc Bishop N; Bouros DE; Antoniou K; Guiot J; Kramer MR; Kirchgaessler KU; Bengus M; Gilberg F; Perjesi A; Harari S; Wells AU
Lancet Respir Med; 2021 Jan; 9(1):85-95. PubMed ID: 32822614
[TBL] [Abstract][Full Text] [Related]
25. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
26. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
[TBL] [Abstract][Full Text] [Related]
27. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Canestaro WJ; Forrester SH; Raghu G; Ho L; Devine BE
Chest; 2016 Mar; 149(3):756-66. PubMed ID: 26836914
[TBL] [Abstract][Full Text] [Related]
28. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
[TBL] [Abstract][Full Text] [Related]
29. Idiopathic pulmonary fibrosis: a treatable disease?
Costabel U
Eur Respir J; 2003 Dec; 22(6):872-3. PubMed ID: 14680070
[No Abstract] [Full Text] [Related]
30. Pirfenidone-induced severe phototoxic reaction in a patient with idiopathic lung fibrosis.
Papakonstantinou E; Prasse A; Schacht V; Kapp A; Raap U
J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1354-6. PubMed ID: 27005406
[TBL] [Abstract][Full Text] [Related]
31. Does interferon-gamma improve pulmonary function in idiopathic pulmonary fibrosis?
Prasse A; Müller KM; Kurz C; Hamm H; Virchow JC
Eur Respir J; 2003 Dec; 22(6):906-11. PubMed ID: 14680077
[TBL] [Abstract][Full Text] [Related]
32. [Pulmonary fibrosis. Classification, diagnosis, therapy].
Costabel U; Guzman J
Internist (Berl); 2003 Jun; 44 Suppl 1():S35-43. PubMed ID: 14567087
[TBL] [Abstract][Full Text] [Related]
33. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled.
Wells AU
Eur Respir J; 2006 Apr; 27(4):664-6. PubMed ID: 16585071
[No Abstract] [Full Text] [Related]
34. Clinical use of evidence-based medicine--clinical questions: Acetylcysteine, a new treatment for an old foe?
Bennett L; Crouse R; Feldstein D
WMJ; 2006 Sep; 105(6):6-7. PubMed ID: 17042410
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory agents for idiopathic pulmonary fibrosis.
Davies HR; Richeldi L; Walters EH
Cochrane Database Syst Rev; 2003; (3):CD003134. PubMed ID: 12917947
[TBL] [Abstract][Full Text] [Related]
36. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
37. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
King TE; Behr J; Brown KK; du Bois RM; Lancaster L; de Andrade JA; Stähler G; Leconte I; Roux S; Raghu G
Am J Respir Crit Care Med; 2008 Jan; 177(1):75-81. PubMed ID: 17901413
[TBL] [Abstract][Full Text] [Related]
38. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.
Jiang C; Huang H; Liu J; Wang Y; Lu Z; Xu Z
PLoS One; 2012; 7(10):e47024. PubMed ID: 23056564
[TBL] [Abstract][Full Text] [Related]
39. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
40. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial.
Raghu G; Depaso WJ; Cain K; Hammar SP; Wetzel CE; Dreis DF; Hutchinson J; Pardee NE; Winterbauer RH
Am Rev Respir Dis; 1991 Aug; 144(2):291-6. PubMed ID: 1859050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
